前列腺癌患者的第二次原发性癌症风险和生存率:全国性的分析
Jihye Hyun1, Jooyoung Lee1, Tuan Thanh Nguyen2
1Department of Applied Statistics, Chung-Ang University, Seoul, Korea.
Prostate international
|February 2, 2026
概括
像放射治疗 (RT) 和激进前列腺切除术 (RP) 这样的前列腺癌治疗会影响第二次原发性癌症 (SPC) 的风险和存活率. 在肺部或结肠SPCs后,RP患者的结肠癌风险较低,生存率更好.
科学领域:
- 在瘤学瘤学.
- 癌症流行病学 癌症流行病学
- 治疗结果 治疗结果
背景情况:
- 前列腺癌 (PC) 治疗可能会影响患第二原发性癌症 (SPC) 的风险.
- 了解这些风险对于长期的患者管理至关重要.
- 之前的研究在治疗特定的SPC风险方面产生了不同的结果.
研究的目的:
- 评估PC患者中SPC的发病率,这些患者接受了激进前列腺切除术 (RP) 和放射治疗 (RT).
- 为了评估SPC诊断后的整体存活率 (OS),与最初的PC治疗相关.
- 为了比较RP和RT组之间的SPC风险和结果.
主要方法:
- 使用了韩国国家健康保险服务数据库 (2002-2018).
- 应用治疗权重的逆概率,以纠正RT和RP组之间的选择偏差.
- 分析了SPC的累积发病率函数和SPC诊断后OS的Cox回归.
主要成果:
- 在26,254名PC患者中,20.3%接受了RT,79.7%接受了RP.
- 与一般男性患者相比,PC患者所有SPC的风险降低了7% (SIR=0.93).
- 膀和甲状腺癌在两组中都比较常见;RP患者在肺和结肠SPC后的结肠癌风险较低,生存率更好,但食道SPC后的死亡风险更高.
结论:
- 最初的PC治疗 (RP与RT) 影响SPC发生率和SPC诊断后的OS.
- 对PC的治疗决定应该考虑SPC的潜在长期风险.
- 对SPC的随访护理和随后的治疗策略应根据所接受的初级PC治疗量身定制.
相关概念视频
Cancer Survival Analysis
765
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
765
Introduction To Survival Analysis
789
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
789
Comparing the Survival Analysis of Two or More Groups
602
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
602
Truncation in Survival Analysis
621
Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
621
Assumptions of Survival Analysis
425
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
425
Cancer
54.3K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.3K


